fda compounding semaglutide warning november 2025 The Risks of Compounded Products New project announcement: HHS‑OIG is

From this perspective, mild thermal sensations after injection are a sign the drug is working not a warning sign

However, some patients may experience symptomatic low blood pressure, particularly when combined with antihypertensive medications, during significant weight loss, or when dehydrated from gastrointestinal side effects

Semaglutide and tirzepatide have been under shortage pressure since 2023 as demand for the branded formulations (Ozempic, Wegovy, Mounjaro, Zepbound) outpaced manufacturing capacity

Semaglutide has also shown potential in reducing the risk of several health complications associated with obesity

Tissue Barriers 12:2292461